CPT® Code 90619

Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use

This CPT® code 90619 refers to the Meningococcal conjugate vaccine, specifically designed to protect against meningococcal disease caused by serogroups A, C, W, and Y. The vaccine utilizes tetanus toxoid as a carrier protein, which aids in the immune response to the four polysaccharides present in the vaccine. Meningococcal disease is a serious infection caused by the bacterium Neisseria meningitides, which is transmitted through respiratory secretions. This infection can lead to severe health complications, including septicemia and meningitis, both of which can progress rapidly and have a high mortality rate if not treated promptly. There are 13 identified serogroups of Neisseria meningitides, with six of these being responsible for the majority of meningococcal disease cases globally. The vaccine represented by this code specifically targets serogroups A, C, W, and Y, providing crucial protection against these strains. The conjugation process used in this vaccine allows for the direct (for W and Y) and indirect (for A and C) linking of the polysaccharides to the tetanus toxoid, which enhances the immune response by producing antibodies against the capsular polysaccharides of these serogroups. Notably, this vaccine is the first of its kind approved for single-dose administration, making it a significant advancement in the prevention of invasive meningococcal disease for individuals aged 12 months and older. It is important to note that this code specifically reports the supply of the vaccine itself, while the administration of the vaccine via intramuscular injection is reported separately.